肝苏颗粒联合替比夫定对慢性乙型肝炎患者血清乙肝标志物水平及肝功能的影响  

Impacts of Gansu granule combined with telbivudine on serum hepatitis B markers level and hepatic function in patients with chronic hepatitis B

作　　者：阮春艳 陈积 黄珍康 陈银众 RUAN Chunyan;CHEN Ji;HUANG Zhenkang;CHEN Yinzhong(Department of Infectious Disease,the Second Affiliated Hospital of Guangdong Medical University,Guangdong,Zhanjiang 524000,China)

机构地区：[1]广东医科大学附属第二医院感染科,广东湛江524000

出　　处：《中国医药科学》2021年第3期109-111,148,共4页China Medicine And Pharmacy

摘　　要：目的探讨肝苏颗粒联合替比夫定治疗慢性乙型肝炎(CHB)对患者肝功能和肝纤维化指标的影响。方法选取2017年6月至2019年6月于广东医科大学附属第二医院就诊的84例CHB患者,按随机数字表法分为两组,每组各42例。对照组予以替比夫定治疗,观察组加用肝苏颗粒治疗。比较两组血清乙肝标志物、肝功能指标和肝纤维化指标,并记录用药期间不良反应发生情况。结果观察组HBsAg转阴率、HBV-DNA转阴率为66.67%、61.90%,高于对照组,差异有统计学意义(P <0.05);治疗后观察组总胆红素(TBIL)、天门冬氨酸氨基转移酶(AST)和丙氨酸氨基转移酶(ALT)为(36.42±4.12)μmol/L、(81.75±7.98) U/L、(85.25±8.01)U/L,低于对照组,差异有统计学意义(P <0.05);观察组治疗后层黏蛋白(LN)、透明质酸(HA)、Ⅲ型前胶原(PCⅢ)为(49.74±5.34)μg/L、(38.65±4.84)μg/L、(23.58±3.44)μg/L,低于对照组,差异有统计学意义(P <0.05);两组不良反应发生率比较,差异无统计学意义(P> 0.05)。结论肝苏颗粒联合替比夫定可加快CHB患者乙肝标志物转移,减轻肝功能损伤,阻止肝纤维化进展,促进病情稳定,安全可靠。Objective To investigate the impacts of Gansu granule combined with telbivudine on hepatic function and hepatic fibrosis indexes in patients with chronic hepatitis B(CHB). Methods A total of 84 CHB patients admitted to the Second Affiliated Hospital of Guangdong Medical University from June 2017 to June 2019 were selected and divided into the control group(n=42) and the observation group(n=42) according to the random number table method. The control group was treated with telbivudine, while the observation group was treated with Gansu granule. The markers of serum hepatitis B, hepatic function indexes and hepatic fibrosis indexes were compared between the two groups, and incidence of adverse reactions(ADRs) during medication period were recorded. Results The negative rates of HBsAg and HBV-DNA in the observation group were 66.67% and 61.90%, respectively, higher than those in the control group, with statistically significant differences(P < 0.05). TBIL, AST and ALT in the observation group after treatment were(36.42±4.12) μmol/L,(81.75±7.98) U/L and(85.25±8.01) U/L respectively, lower than those in the control group, with statistically significant differences(P < 0.05). The levels of LN, HA and PCIII in the observation group after treatment were(49.74±5.34) μg/L,(38.65±4.84) μg/L and(23.58±3.44) μg/L, respectively, lower than those in the control group, with statistically significant differences(P < 0.05). There was no statistically significant difference in the incidence of ADRs between the two groups(P > 0.05). Conclusion Gansu granule combined with telbivudine can accelerate the transfer of hepatitis B markers in patients with CHB, reduce hepatic function damage, prevent the progress of hepatic fibrosis, and promote the stability of the disease, which is safe and reliable.

关 键 词：慢性乙型肝炎 肝苏颗粒 替比夫定 乙肝标志物 肝功能 不良反应 

分 类 号：R512.62[医药卫生—内科学]